PPARγ agonists (Pioglitazone, rosilglitazone) showed some benefit with their antifibrotic properties but didn’t gain widespread use because of their side effects like risk of bladder cancer, cardiac events and weight gain5. This evidence concerns the gene PPARG and urinary bladder carcinoma.